237 related articles for article (PubMed ID: 29679665)
1. Comparison of exosomes and ferritin protein nanocages for the delivery of membrane protein therapeutics.
Cho E; Nam GH; Hong Y; Kim YK; Kim DH; Yang Y; Kim IS
J Control Release; 2018 Jun; 279():326-335. PubMed ID: 29679665
[TBL] [Abstract][Full Text] [Related]
2. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
3. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
4. Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity.
Choi Y; Nam GH; Kim GB; Kim S; Kim YK; Kim SA; Kim HJ; Lee EJ; Kim IS
Cancer Gene Ther; 2021 Sep; 28(9):960-970. PubMed ID: 34349240
[TBL] [Abstract][Full Text] [Related]
5. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
6. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
7. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
[TBL] [Abstract][Full Text] [Related]
8. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
9. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
10. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
11. Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer.
Shimizu A; Sawada K; Kobayashi M; Yamamoto M; Yagi T; Kinose Y; Kodama M; Hashimoto K; Kimura T
Mol Cancer Res; 2021 Sep; 19(9):1583-1595. PubMed ID: 34016744
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
13. The CD47-SIRPα signalling system: its physiological roles and therapeutic application.
Murata Y; Kotani T; Ohnishi H; Matozaki T
J Biochem; 2014 Jun; 155(6):335-44. PubMed ID: 24627525
[TBL] [Abstract][Full Text] [Related]
14. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
Matozaki T; Murata Y; Okazawa H; Ohnishi H
Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
[TBL] [Abstract][Full Text] [Related]
15. Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.
Cheng L; Zhang X; Tang J; Lv Q; Liu J
Biomaterials; 2021 Aug; 275():120964. PubMed ID: 34147721
[TBL] [Abstract][Full Text] [Related]
16. Anti-SIRP
Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
[TBL] [Abstract][Full Text] [Related]
17. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
18. Ferritin nanocage with intrinsically disordered proteins and affibody: A platform for tumor targeting with extended pharmacokinetics.
Lee NK; Lee EJ; Kim S; Nam GH; Kih M; Hong Y; Jeong C; Yang Y; Byun Y; Kim IS
J Control Release; 2017 Dec; 267():172-180. PubMed ID: 28821462
[TBL] [Abstract][Full Text] [Related]
19. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
[TBL] [Abstract][Full Text] [Related]
20. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]